Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 285

1.

Acute Flaccid Myelitis in the United States: 2015-2017.

Ayers T, Lopez A, Lee A, Kambhampati A, Nix WA, Henderson E, Rogers S, Weldon WC, Oberste MS, Sejvar J, Hopkins SE, Pallansch MA, Routh JA, Patel M.

Pediatrics. 2019 Oct 7. pii: e20191619. doi: 10.1542/peds.2019-1619. [Epub ahead of print]

PMID:
31591135
2.

Using a noninfectious MVM surrogate for assessing viral clearance during downstream process development.

Orchard JD, Cetlin D, Pallansch M, Barlow R, Borman J, Dhar A, Pallansch L, Dickson M.

Biotechnol Prog. 2019 Oct 6:e2921. doi: 10.1002/btpr.2921. [Epub ahead of print]

PMID:
31587529
3.

Immunogenicity of full and fractional dose of inactivated poliovirus vaccine for use in routine immunisation and outbreak response: an open-label, randomised controlled trial.

Snider CJ, Zaman K, Estivariz CF, Yunus M, Weldon WC, Wannemuehler KA, Oberste MS, Pallansch MA, Wassilak SG, Bari TIA, Anand A.

Lancet. 2019 Jun 29;393(10191):2624-2634. doi: 10.1016/S0140-6736(19)30503-3. Epub 2019 May 16.

PMID:
31104832
4.

Characterising the costs of the Global Polio Laboratory Network: a survey-based analysis.

Duintjer Tebbens RJ, Diop OM, Pallansch MA, Oberste MS, Thompson KM.

BMJ Open. 2019 Jan 21;9(1):e023290. doi: 10.1136/bmjopen-2018-023290.

5.

Increase in Acute Flaccid Myelitis - United States, 2018.

McKay SL, Lee AD, Lopez AS, Nix WA, Dooling KL, Keaton AA, Spence-Davizon E, Herlihy R, Clark TA, Hopkins SE, Pastula DM, Sejvar J, Oberste MS, Pallansch MA, Patel M, Routh JA.

MMWR Morb Mortal Wkly Rep. 2018 Nov 16;67(45):1273-1275. doi: 10.15585/mmwr.mm6745e1.

6.

Immune Priming and Long-term Persistence of Memory B Cells After Inactivated Poliovirus Vaccine in Macaque Models: Support for at least 2 Doses.

Bhaumik SK, Kulkarni RR, Weldon WC, Silveira ELV, Ahmed H, Gunisetty S, Chandele A, Antia R, Verma H, Sutter R, Pallansch MA, Oberste MS, Villinger F, Orenstein W, Murali-Krishna K.

Clin Infect Dis. 2018 Oct 30;67(suppl_1):S66-S77. doi: 10.1093/cid/ciy634.

7.

Modeling Undetected Live Poliovirus Circulation After Apparent Interruption of Transmission: Pakistan and Afghanistan.

Kalkowska DA, Duintjer Tebbens RJ, Pallansch MA, Thompson KM.

Risk Anal. 2019 Feb;39(2):402-413. doi: 10.1111/risa.13214. Epub 2018 Oct 8.

PMID:
30296340
8.

Use of a noninfectious surrogate to predict minute virus of mice removal during nanofiltration.

Cetlin D, Pallansch M, Fulton C, Vyas E, Shah A, Sohka T, Dhar A, Pallansch L, Strauss D.

Biotechnol Prog. 2018 Sep;34(5):1213-1220. doi: 10.1002/btpr.2694. Epub 2018 Sep 8.

PMID:
30194917
9.

Ending Use of Oral Poliovirus Vaccine - A Difficult Move in the Polio Endgame.

Pallansch MA.

N Engl J Med. 2018 Aug 30;379(9):801-803. doi: 10.1056/NEJMp1808903. No abstract available.

10.

Breaking the Last Chains of Poliovirus Transmission: Progress and Challenges in Global Polio Eradication.

Kew O, Pallansch M.

Annu Rev Virol. 2018 Sep 29;5(1):427-451. doi: 10.1146/annurev-virology-101416-041749. Epub 2018 Jul 12. Review.

PMID:
30001183
11.

Progress in Vaccine-Preventable and Respiratory Infectious Diseases-First 10 Years of the CDC National Center for Immunization and Respiratory Diseases, 2006-2015.

Schuchat A, Anderson LJ, Rodewald LE, Cox NJ, Hajjeh R, Pallansch MA, Messonnier NE, Jernigan DB, Wharton M.

Emerg Infect Dis. 2018 Jul;24(7):1178-1187. doi: 10.3201/eid2407.171699.

12.

Immunogenicity of type 2 monovalent oral and inactivated poliovirus vaccines for type 2 poliovirus outbreak response: an open-label, randomised controlled trial.

Zaman K, Estívariz CF, Morales M, Yunus M, Snider CJ, Gary HE Jr, Weldon WC, Oberste MS, Wassilak SG, Pallansch MA, Anand A.

Lancet Infect Dis. 2018 Jun;18(6):657-665. doi: 10.1016/S1473-3099(18)30113-0. Epub 2018 Mar 20.

PMID:
29571817
13.

The seasonality of nonpolio enteroviruses in the United States: Patterns and drivers.

Pons-Salort M, Oberste MS, Pallansch MA, Abedi GR, Takahashi S, Grenfell BT, Grassly NC.

Proc Natl Acad Sci U S A. 2018 Mar 20;115(12):3078-3083. doi: 10.1073/pnas.1721159115. Epub 2018 Mar 5.

14.

Modeling Poliovirus Transmission in Pakistan and Afghanistan to Inform Vaccination Strategies in Undervaccinated Subpopulations.

Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Ehrhardt DT, Farag NH, Hadler SC, Hampton LM, Martinez M, Wassilak SGF, Thompson KM.

Risk Anal. 2018 Aug;38(8):1701-1717. doi: 10.1111/risa.12962. Epub 2018 Jan 3.

PMID:
29314143
15.

Patients with Primary Immunodeficiencies Are a Reservoir of Poliovirus and a Risk to Polio Eradication.

Aghamohammadi A, Abolhassani H, Kutukculer N, Wassilak SG, Pallansch MA, Kluglein S, Quinn J, Sutter RW, Wang X, Sanal O, Latysheva T, Ikinciogullari A, Bernatowska E, Tuzankina IA, Costa-Carvalho BT, Franco JL, Somech R, Karakoc-Aydiner E, Singh S, Bezrodnik L, Espinosa-Rosales FJ, Shcherbina A, Lau YL, Nonoyama S, Modell F, Modell V; JMF Centers Network Investigators and Study Collaborators, Barbouche MR, McKinlay MA.

Front Immunol. 2017 Jun 13;8:685. doi: 10.3389/fimmu.2017.00685. eCollection 2017.

16.

ICTV Virus Taxonomy Profile: Picornaviridae.

Zell R, Delwart E, Gorbalenya AE, Hovi T, King AMQ, Knowles NJ, Lindberg AM, Pallansch MA, Palmenberg AC, Reuter G, Simmonds P, Skern T, Stanway G, Yamashita T, Ictv Report Consortium.

J Gen Virol. 2017 Oct;98(10):2421-2422. doi: 10.1099/jgv.0.000911. Epub 2017 Sep 8.

17.

The Global Polio Laboratory Network as a Platform for the Viral Vaccine-Preventable and Emerging Diseases Laboratory Networks.

Diop OM, Kew OM, de Gourville EM, Pallansch MA.

J Infect Dis. 2017 Jul 1;216(suppl_1):S299-S307. doi: 10.1093/infdis/jix092.

18.

The role of supplementary environmental surveillance to complement acute flaccid paralysis surveillance for wild poliovirus in Pakistan - 2011-2013.

Cowger TL, Burns CC, Sharif S, Gary HE Jr, Iber J, Henderson E, Malik F, Zahoor Zaidi SS, Shaukat S, Rehman L, Pallansch MA, Orenstein WA.

PLoS One. 2017 Jul 25;12(7):e0180608. doi: 10.1371/journal.pone.0180608. eCollection 2017.

19.

Insights from a Systematic Search for Information on Designs, Costs, and Effectiveness of Poliovirus Environmental Surveillance Systems.

Duintjer Tebbens RJ, Zimmermann M, Pallansch MA, Thompson KM.

Food Environ Virol. 2017 Dec;9(4):361-382. doi: 10.1007/s12560-017-9314-4. Epub 2017 Jul 7. Review.

PMID:
28687986
20.

Immunogenicity to poliovirus type 2 following two doses of fractional intradermal inactivated poliovirus vaccine: A novel dose sparing immunization schedule.

Anand A, Molodecky NA, Pallansch MA, Sutter RW.

Vaccine. 2017 May 19;35(22):2993-2998. doi: 10.1016/j.vaccine.2017.03.008. Epub 2017 Apr 20. Review.

PMID:
28434691
21.

Guidance for Assessment of Poliovirus Vaccination Status and Vaccination of Children Who Have Received Poliovirus Vaccine Outside the United States.

Marin M, Patel M, Oberste S, Pallansch MA.

MMWR Morb Mortal Wkly Rep. 2017 Jan 13;66(1):23-25. doi: 10.15585/mmwr.mm6601a6. Erratum in: MMWR Morb Mortal Wkly Rep. 2017 Feb 17;66(6):180.

22.

Acute Flaccid Myelitis in the United States, August-December 2014: Results of Nationwide Surveillance.

Sejvar JJ, Lopez AS, Cortese MM, Leshem E, Pastula DM, Miller L, Glaser C, Kambhampati A, Shioda K, Aliabadi N, Fischer M, Gregoricus N, Lanciotti R, Nix WA, Sakthivel SK, Schmid DS, Seward JF, Tong S, Oberste MS, Pallansch M, Feikin D.

Clin Infect Dis. 2016 Sep 15;63(6):737-745. doi: 10.1093/cid/ciw372. Epub 2016 Jun 17.

23.

Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame.

Duintjer Tebbens RJ, Pallansch MA, Wassilak SG, Cochi SL, Thompson KM.

BMC Infect Dis. 2016 Mar 24;16:137. doi: 10.1186/s12879-016-1465-7.

24.

Standardized Methods for Detection of Poliovirus Antibodies.

Weldon WC, Oberste MS, Pallansch MA.

Methods Mol Biol. 2016;1387:145-76. doi: 10.1007/978-1-4939-3292-4_8.

PMID:
26983734
25.

Maintenance and Intensification of Bivalent Oral Poliovirus Vaccine Use Prior to its Coordinated Global Cessation.

Tebbens RJD, Hampton LM, Wassilak SGF, Pallansch MA, Cochi SL, Thompson KM.

J Vaccines Vaccin. 2016 Oct;7(5). pii: 340. doi: 10.4172/2157-7560.1000340. Epub 2016 Oct 3.

26.

Multifacility Outbreak of Middle East Respiratory Syndrome in Taif, Saudi Arabia.

Assiri A, Abedi GR, Bin Saeed AA, Abdalla MA, al-Masry M, Choudhry AJ, Lu X, Erdman DD, Tatti K, Binder AM, Rudd J, Tokars J, Miao C, Alarbash H, Nooh R, Pallansch M, Gerber SI, Watson JT.

Emerg Infect Dis. 2016 Jan;22(1):32-40. doi: 10.3201/eid2201.151370.

27.

Severe respiratory illness associated with a nationwide outbreak of enterovirus D68 in the USA (2014): a descriptive epidemiological investigation.

Midgley CM, Watson JT, Nix WA, Curns AT, Rogers SL, Brown BA, Conover C, Dominguez SR, Feikin DR, Gray S, Hassan F, Hoferka S, Jackson MA, Johnson D, Leshem E, Miller L, Nichols JB, Nyquist AC, Obringer E, Patel A, Patel M, Rha B, Schneider E, Schuster JE, Selvarangan R, Seward JF, Turabelidze G, Oberste MS, Pallansch MA, Gerber SI; EV-D68 Working Group.

Lancet Respir Med. 2015 Nov;3(11):879-87. doi: 10.1016/S2213-2600(15)00335-5. Epub 2015 Oct 5.

28.

Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial.

Anand A, Zaman K, Estívariz CF, Yunus M, Gary HE, Weldon WC, Bari TI, Steven Oberste M, Wassilak SG, Luby SP, Heffelfinger JD, Pallansch MA.

Vaccine. 2015 Nov 27;33(48):6816-22. doi: 10.1016/j.vaccine.2015.09.039. Epub 2015 Oct 23.

PMID:
26476367
29.

An economic analysis of poliovirus risk management policy options for 2013-2052.

Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SG, Thompson KM.

BMC Infect Dis. 2015 Sep 24;15:389. doi: 10.1186/s12879-015-1112-8.

30.

Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs.

Duintjer Tebbens RJ, Pallansch MA, Thompson KM.

BMC Infect Dis. 2015 Sep 17;15:379. doi: 10.1186/s12879-015-1115-5.

31.

CDC's Early Response to a Novel Viral Disease, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), September 2012-May 2014.

Williams HA, Dunville RL, Gerber SI, Erdman DD, Pesik N, Kuhar D, Mason KA, Haynes L, Rotz L, St Pierre J, Poser S, Bunga S, Pallansch MA, Swerdlow DL; MERS-CoV Working Group.

Public Health Rep. 2015 Jul-Aug;130(4):307-17.

32.

Immunogenicity of three doses of bivalent, trivalent, or type 1 monovalent oral poliovirus vaccines with a 2 week interval between doses in Bangladesh: an open-label, non-inferiority, randomised, controlled trial.

Estívariz CF, Anand A, Gary HE Jr, Rahman M, Islam J, Bari TI, Wassilak SG, Chu SY, Weldon WC, Pallansch MA, Heffelfinger JD, Luby SP, Zaman K.

Lancet Infect Dis. 2015 Aug;15(8):898-904. doi: 10.1016/S1473-3099(15)00094-8. Epub 2015 Jun 17.

PMID:
26093980
33.

Combinations of Quality and Frequency of Immunization Activities to Stop and Prevent Poliovirus Transmission in the High-Risk Area of Northwest Nigeria.

Duintjer Tebbens RJ, Pallansch MA, Wassilak SG, Cochi SL, Thompson KM.

PLoS One. 2015 Jun 11;10(6):e0130123. doi: 10.1371/journal.pone.0130123. eCollection 2015.

34.

Modeling undetected live poliovirus circulation after apparent interruption of transmission: implications for surveillance and vaccination.

Kalkowska DA, Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SG, Thompson KM.

BMC Infect Dis. 2015 Feb 18;15:66. doi: 10.1186/s12879-015-0791-5.

35.

Effect of time at temperature on wild poliovirus titers in stool specimens.

Walker AT, Williams AJ, Gary HE Jr, Pallansch MA, Wassilak SG, Oberste MS.

Virology. 2015 Aug;482:28-31. doi: 10.1016/j.virol.2015.03.005. Epub 2015 Mar 30.

36.

Update on the epidemiology of Middle East respiratory syndrome coronavirus (MERS-CoV) infection, and guidance for the public, clinicians, and public health authorities - January 2015.

Rha B, Rudd J, Feikin D, Watson J, Curns AT, Swerdlow DL, Pallansch MA, Gerber SI; Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2015 Jan 30;64(3):61-2.

37.

Expansion of syndromic vaccine preventable disease surveillance to include bacterial meningitis and Japanese encephalitis: evaluation of adapting polio and measles laboratory networks in Bangladesh, China and India, 2007-2008.

Cavallaro KF, Sandhu HS, Hyde TB, Johnson BW, Fischer M, Mayer LW, Clark TA, Pallansch MA, Yin Z, Zuo S, Hadler SC, Diorditsa S, Hasan AS, Bose AS, Dietz V; AMES Study Group.

Vaccine. 2015 Feb 25;33(9):1168-75. doi: 10.1016/j.vaccine.2015.01.004. Epub 2015 Jan 15.

38.

Modeling options to manage type 1 wild poliovirus imported into Israel in 2013.

Kalkowska DA, Duintjer Tebbens RJ, Grotto I, Shulman LM, Anis E, Wassilak SG, Pallansch MA, Thompson KM.

J Infect Dis. 2015 Jun 1;211(11):1800-12. doi: 10.1093/infdis/jiu674. Epub 2014 Dec 10.

PMID:
25505296
39.

Zinc supplementation fails to increase the immunogenicity of oral poliovirus vaccine: a randomized controlled trial.

Habib MA, Soofi S, Sheraz A, Bhatti ZS, Okayasu H, Zaidi SZ, Molodecky NA, Pallansch MA, Sutter RW, Bhutta ZA.

Vaccine. 2015 Feb 4;33(6):819-25. doi: 10.1016/j.vaccine.2014.12.001. Epub 2014 Dec 11.

PMID:
25500307
40.

Health care worker contact with MERS patient, Saudi Arabia.

Hall AJ, Tokars JI, Badreddine SA, Saad ZB, Furukawa E, Al Masri M, Haynes LM, Gerber SI, Kuhar DT, Miao C, Trivedi SU, Pallansch MA, Hajjeh R, Memish ZA.

Emerg Infect Dis. 2014 Dec;20(12):2148-51. doi: 10.3201/eid2012.141211.

41.

Dominant drug targets suppress the emergence of antiviral resistance.

Tanner EJ, Liu HM, Oberste MS, Pallansch M, Collett MS, Kirkegaard K.

Elife. 2014 Nov 3;3. doi: 10.7554/eLife.03830.

42.

Development of an efficient entire-capsid-coding-region amplification method for direct detection of poliovirus from stool extracts.

Arita M, Kilpatrick DR, Nakamura T, Burns CC, Bukbuk D, Oderinde SB, Oberste MS, Kew OM, Pallansch MA, Shimizu H.

J Clin Microbiol. 2015 Jan;53(1):73-8. doi: 10.1128/JCM.02384-14. Epub 2014 Oct 22.

43.

Estimating the likely coverage of inactivated poliovirus vaccine in routine immunization: evidence from demographic and health surveys.

Anand A, Pallansch MA, Estivariz CF, Gary H, Wassilak SG.

J Infect Dis. 2014 Nov 1;210 Suppl 1:S465-74. doi: 10.1093/infdis/jiu343.

PMID:
25316869
44.

Progress in the development of poliovirus antiviral agents and their essential role in reducing risks that threaten eradication.

McKinlay MA, Collett MS, Hincks JR, Oberste MS, Pallansch MA, Okayasu H, Sutter RW, Modlin JF, Dowdle WR.

J Infect Dis. 2014 Nov 1;210 Suppl 1:S447-53. doi: 10.1093/infdis/jiu043. Review.

PMID:
25316866
45.

Individual-based modeling of potential poliovirus transmission in connected religious communities in North America with low uptake of vaccination.

Kisjes KH, Duintjer Tebbens RJ, Wallace GS, Pallansch MA, Cochi SL, Wassilak SG, Thompson KM.

J Infect Dis. 2014 Nov 1;210 Suppl 1:S424-33. doi: 10.1093/infdis/jit843.

PMID:
25316864
46.

Effect of buffer on the immune response to trivalent oral poliovirus vaccine in Bangladesh: a community based randomized controlled trial.

Chandir S, Ahamed KU, Baqui AH, Sutter RW, Okayasu H, Pallansch MA, Oberste MS, Moulton LH, Halsey NA.

J Infect Dis. 2014 Nov 1;210 Suppl 1:S390-7. doi: 10.1093/infdis/jiu378.

PMID:
25316860
47.

Phylogeny of imported and reestablished wild polioviruses in theDemocratic Republic of the Congo from 2006 to 2011.

Gumede N, Jorba J, Deshpande J, Pallansch M, Yogolelo R, Muyembe-Tamfum JJ, Kew O, Venter M, Burns CC.

J Infect Dis. 2014 Nov 1;210 Suppl 1:S361-7. doi: 10.1093/infdis/jiu375.

48.

Outbreak of type 1 wild poliovirus infection in adults, Namibia, 2006.

Yusuf N, de Wee R, Foster N, Watkins MA, Tiruneh D, Chauvin C, Bossarte R, Mandlhate C, Jack A, Gumede N, Mawela A, Burns CC, Pallansch MA, Allies T, Rainey J, Mataruse N, Nshimirimana D.

J Infect Dis. 2014 Nov 1;210 Suppl 1:S353-60. doi: 10.1093/infdis/jiu069.

PMID:
25316855
49.

Switch from oral to inactivated poliovirus vaccine in Yogyakarta Province, Indonesia: summary of coverage, immunity, and environmental surveillance.

Wahjuhono G, Revolusiana, Widhiastuti D, Sundoro J, Mardani T, Ratih WU, Sutomo R, Safitri I, Sampurno OD, Rana B, Roivainen M, Kahn AL, Mach O, Pallansch MA, Sutter RW.

J Infect Dis. 2014 Nov 1;210 Suppl 1:S347-52. doi: 10.1093/infdis/jiu060. Erratum in: J Infect Dis. 2015 Jun 1;211(11):1855.

PMID:
25316854
50.

Detection of vaccine-derived polioviruses in Mexico using environmental surveillance.

Esteves-Jaramillo A, Estívariz CF, Peñaranda S, Richardson VL, Reyna J, Coronel DL, Carrión V, Landaverde JM, Wassilak SG, Pérez-Sánchez EE, López-Martínez I, Burns CC, Pallansch MA.

J Infect Dis. 2014 Nov 1;210 Suppl 1:S315-23. doi: 10.1093/infdis/jiu183.

PMID:
25316850

Supplemental Content

Loading ...
Support Center